Top Medical Searches

FDA Approves Siliq (brodalumab) for Plaque Psoriasis

February 15, 2017 — The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection.
Siliq is intended for patients who are candidates for… Read More..

February 14th, 2017

Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen

CHARLESTON, S.C.–(BUSINESS WIRE) February 13, 2017 –Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of… Read More..

February 12th, 2017

FDA Approves Emflaza (deflazacort) to treat Duchenne Muscular Dystrophy

February 9, 2017 — The U.S. Food and Drug Administration today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes… Read More..

February 9th, 2017

FDA Approves Amgen’s Parsabiv (etelcalcetide) for Secondary Hyperparathyroidism in Adult Patients on Hemodialysis

THOUSAND OAKS, Calif., Feb. 7, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients… Read More..

February 8th, 2017

Flexion Therapeutics Announces NDA for Zilretta (FX006) Accepted by U.S. FDA

BURLINGTON, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for its lead… Read More..

February 6th, 2017
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us